Halozyme Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Halozyme Therapeutics, Inc. had total assets of $2.53bn, total liabilities of $2.48bn and shareholders' equity of $48.8m. It held $134m in cash against $2.18bn of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Halozyme Therapeutics, Inc.: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	67	83	52	100	27	61	43	67	169	58	120	148	119	234	118	116	134	163
Receivables	—	2	2	16	9	9	32	16	22	30	59	98	91	187	233	288	426	453
Inventory	—	0	1	3	6	6	9	15	5	23	29	61	54	100	128	142	176	137
Total current assets	—	89	64	131	95	161	172	257	510	428	543	555	926	739	746	1,085	825	933
Goodwill	—	—	—	—	—	—	—	—	—	—	—	—	0	409	417	417	580	582
Total assets	—	91	66	135	102	166	182	262	520	440	566	580	1,104	1,842	1,733	2,063	2,525	2,577
Accounts payable	—	4	8	2	3	3	4	4	8	4	6	2	2	18	12	10	21	24
Deferred revenue (current)	—	3	4	9	7	7	9	5	7	4	4	2	2	3	—	—	—	—
Total current liabilities	—	15	17	19	25	24	62	55	131	149	86	421	117	131	112	139	177	344
Short-term debt	—	—	—	0	0	0	22	17	77	92	20	397	89	13	0	0	0	209
Long-term debt	—	—	0	30	50	50	28	199	125	35	383	0	787	1,493	1,499	1,506	2,143	1,938
Total debt	0	0	0	30	50	50	50	221	205	128	480	397	896	1,538	1,525	1,525	2,180	2,147
Total liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—	1,672	1,649	1,700	2,477	2,434
Shareholders' equity	7	20	11	49	−20	41	43	−32	208	249	92	151	197	170	84	364	49	144
Shares outstanding	—	101m	104m	113m	115m	126m	128m	130m	143m	145m	137m	135m	137m	135m	127m	123m	118m	114m

US$ millions unless shown otherwise. Fiscal quarters.

Halozyme Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	273	288	304	315	344	426	458	453
Inventory	131	142	165	182	186	176	155	137
Total current assets	1,127	1,085	1,262	1,123	1,329	825	1,003	933
Goodwill	417	417	417	417	417	580	582	582
Total assets	2,118	2,063	2,197	2,054	2,221	2,525	2,673	2,577
Accounts payable	12	10	20	19	15	21	14	24
Total current liabilities	109	139	150	134	837	177	363	344
Short-term debt	—	0	—	—	711	0	209	209
Long-term debt	1,504	1,506	1,507	1,509	800	2,143	1,936	1,938
Total debt	1,504	1,506	1,507	1,509	1,511	2,143	2,145	2,147
Total liabilities	1,665	1,700	1,714	1,721	1,717	2,477	2,453	2,434
Shareholders' equity	453	364	482	333	504	49	220	144
Shares outstanding	127m	123m	123m	118m	118m	118m	119m	114m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALKS vs HALO HALO vs INSM HALO vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Halozyme Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Halozyme Therapeutics, Inc.